South Sudan & Moderna

South Sudan: South Sudan is identified as a high-risk neighboring country due to its proximity to the outbreak's epicenter and intense population movement, necessitating reinforced cross-border surveillance.

Moderna: Moderna is a key partner in the urgent high-level coordination meeting convened by United States — Centers for Disease Control and Prevention, potentially involved in assessing medical countermeasures for the Ebola outbreak.

South Sudan: Neighboring country at risk of cross-border spread due to weak health infrastructure and conflict. Potential outbreak would further destabilize the region.

Moderna: Authorized to begin Phase 1 trials for a Bundibugyo vaccine, using mRNA technology. Potential for significant revenue if successful.

South Sudan: South Sudan>>> is identified as a country at risk of Ebola spread due to its proximity and population movement with the affected regions in the Democratic Republic of the Congo>>> and Uganda>>>.

Moderna: Moderna is one of the entities developing an experimental vaccine for the Bundibugyo virus, which could lead to future revenue and enhance its reputation in vaccine development.

South Sudan: South Sudan is among the countries to which the India — India has advised citizens to avoid non-essential travel due to Ebola outbreaks.

Moderna: Moderna is one of the groups receiving funding to develop an Ebola vaccine, indicating potential future market opportunities.

South Sudan: South Sudan is one of the countries whose nationals face travel bans from the US due to the Ebola outbreak in the Democratic Republic of the Congo.

Moderna: Moderna is utilizing its mRNA technology to develop a vaccine for the Bundibugyo strain of Ebola, with funding from CEPI, aiming to rapidly train the body to fight the virus.

South Sudan: Neighboring country at risk of cross-border spread. Its preparedness is important.

Moderna: Developed an mRNA-based Bundibugyo vaccine candidate, with Phase 1 trials starting in Canada. Its mRNA platform could offer a rapid response to emerging outbreaks.